跳至主要内容
临床试验/JPRN-jRCT1031220705
JPRN-jRCT1031220705招募中3 期

JCOG2202: Randomized phase III trial of laparoscopic versus open distal pancreatectomy for pancreatic cancer - LAPAN study

akamura Masafumi0 个研究点目标入组 370 人开始时间: 2023年3月14日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
370

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 <= 85age old(—)
性别
All

入选标准

  • (1) Pancreatic tumor diagnosed by contrast-enhanced abdominal computed tomography (CT) meeting either one of the following conditions.
  • (i) Histologically proven invasive ductal carcinoma (adenocarcinoma or adenosquamous carcinoma)
  • (ii) Cytologically proven Class IV or Class V
  • In case of the following conditions, pancreatic tumor radiologically compatible with invasive ductal carcinoma is eligible without pathological diagnosis.
  • (a) No neoadjuvant chemotherapy
  • (b) Endoscopic ultrasound-guided tissue acquisition or endoscopic retrograde cholangiopancreatography can not be performed safely.
  • (2) Tumor located in the body or tail of the pancreas.
  • (3) Resectable pancreatic cancer by contrast-enhanced CT. Patients treated with preoperative chemotherapy fulfill both (i) and (ii).
  • (i) Resectable pancreatic cancer before chemotherapy.
  • (ii) Resectable pancreatic cancer after chemotherapy.
  • (4) Muximum length of the tumor <= 8 cm.
  • (5) Curative resection is possible by distal pancreatectomy with regional lymph node dissection.
  • (6) In case of the preceding diagnostic laparoscopy, peritoneal cytology is negative.
  • (7) No invasion to the portal vein or other organs except for the adrenal gland or spleen.
  • (8) Aged between18 and 85 years old.
  • (9) Performance status (ECOG) of 0 or 1.
  • (10) No prior treatment of radiation therapy against pancreatic cancer.
  • (11) No history of upper abdominal surgery except for laparoscopic cholecystectomy.
  • (12) Sufficient organ functions.
  • (13) Written informed consent.

排除标准

  • (1) Synchronous or metachronous (within 5 years) malignancies.
  • (2) Infectious disease that requires systemic treatment.
  • (3) Body temperature of 38.0 degrees Celsius or higher.
  • (4) During pregnancy, within 28 days of postparturition, or during lactation.
  • (5) Severe mental disease.
  • (6) Receiving continuous systemic corticosteroid or immunosuppressive treatment.
  • (7) Severe comorbidities (such as heart failure, renal failure, liver failure, hemorrhagic peptic ulcer, intestinal obstruction, and poorly controlled hypertension).
  • (8) History of unstable angina pectoris within3 weeks or myocardial infarction within 6 months before registration.
  • (9) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema diagnosed by chest X-ray.
  • (10) Iodide is not allowed because of allergy, renal failure, or bronchial asthma.

研究者

发起方
akamura Masafumi

相似试验